PROPANC BIOPHARMA, INC.
Cash Flow Statement
| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-6.4M | $-3.1M | $-4.8M | $-54.1M | $-430.2K | $-354.3K | $-526.7K | $-584.4K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $316 | $229 | $125 | $0 | — | — | $49 | $114 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | $3.0M | — | — | — | — | — |
| Net Cash from Operating Activities | $-1.1M | $-999.1K | $-1.9M | $-96.2K | $18.7K | $-235.5K | $-102.8K | $-238.9K |
| Investing Activities | ||||||||
| Capital Expenditures | $154 | $2.3K | $2.5K | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | $-2.5K | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | $2.5M | — | — | $215.7K | — | — |
| Net Change in Cash | — | — | $590.6K | — | — | $-11.8K | — | — |
| Free Cash Flow | $-1.1M | $-1.0M | $-1.9M | — | — | — | — | — |